A new way to flow
ReelReactor®
Pure. Precise. Scalable.
Gentle enough for biology’s most sensitive reactions.
Tough enough for the most demanding chemistry.
Perfect Consistency
ReelReactor is a continuous micro-batch reactor. Its consumable consists of a cylindrical body around which a long tube is helically wound, forming multiple loops.
As the consumable rotates, rollers compress the tubing against the drum, dividing it into a procession of micro-batches.
Each advances forward by peristaltic motion under constant mixing, ensuring uniform residence time and reaction conditions from start to finish.
Every drop of product leaving ReelReactor has the same formulation and the same reaction time.
Breakthrough Enabled
For biology
The life science industry is still largely reliant on batch manufacturing, which creates massive scalability hurdles, introduces variability in quality, and drives costs to unsustainable levels. Current options for continuous reactors are limited — some face scalability challenges, while others depend on carrier fluids that add unwanted complexity, validation burden, and downstream separation steps.
For chemistry
Industrial chemistry also struggles with batch-based limitations. Large-volume processes pose safety risks — exothermic reactions can run away or even explode. Beyond safety, batch production also creates challenges with quality, overhead, and control over reaction conditions. ReelReactor’s micro-batch approach makes reactions more predictable, controlled, and inherently safer, while reducing operational complexity.
ReelReactor mechanically divides a single tube into many micro-batches without carrier fluids or gases. Liquids remain isolated within the tubing and never contact reactor hardware.
Each micro-batch is mixed for the entire residence time, improving uniformity and reproducibility across runs.
Wetted components — tubing, O-rings, rotary seals — can be specified for biocompatibility or chemical resistance.
ReelReactor’s rotary seal (fluidic interface) can be designed to accept virtually any number of inputs. This makes it possible to combine multiple reagents or formulations without a practical upper limit, supporting complex workflows.
A single consumable, rotating at a constant speed, is capable of performing multiple reactions in parallel or in series, each with unique (and specified) reaction times. This highly customized solution pushes efficiency to the next level.
Throughput is tuned by changing tubing diameter or loop count. The same design supports feasibility studies, process development, or full production.
Our first product, the ReelReactor Discovery Platform, is designed for feasibility studies and early-stage development. It gives researchers a practical way to explore new reactions with precision, reproducibility, and a clear path to scale-up.
Leadership Team
Meet the team leading the way with ReelReactor®
Founder & CEO
Invented, prototyped, and executed biological testing on >10 cell and gene therapy automation & manufacturing technologies, including Thermo Fisher’s Xenon (gene editing) and DynaCellect (cell isolation) platforms. Inventor on more than ten patents in cell therapy automation. Spent six years working hands-on in a BSL-2 lab automating CAR-T manufacturing before founding ReelReactor to solve critical bottlenecks in biomanufacturing.
Lead Engineer
Mechanical engineer since 1989 with a career in designing and testing advanced life science technologies. Operates his own machine shop specializing in rapid prototyping and precision fabrication. Since joining ReelReactor in 2022, he has designed and built the 4th, 5th, and 6th generation systems, and now leads development of the next major platform.
Industry Leaders
Stay informed about breakthrough developments in biologics manufacturing and continious process innovation.
Drugmakers have been slow to adopt the production process, which experts say can streamline operations, boost data quality and reduce time to market.
In recent decades, extensive investigations on the human genome have unveiled numerous genes associated with genetic diseases and consequently led to the emergence of a therapeutic approach called gene therapy.
The forward movement of the biopharma industry is driven by fast-paced advancement in manufacturing technology innovations. As manufacturing technology advances, so does the shift to continuous manufacturing (CM), a process that enables real-time monitoring, improved scalability, and enhanced quality control.
Numerous articles have been published within the last years in chemical science and business media (including this one) on the advantages of continuous reactions, aka flow chemistry.
While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.
